Clinical Trial Detail

NCT ID NCT04224272
Title A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Zymeworks Inc.
Indications

Her2-receptor positive breast cancer

Therapies

Fulvestrant + Palbociclib + ZW25

Age Groups: adult senior

Additional content available in CKB BOOST